Evaluating the role of inflammation in chronic airways disease: The ERICA study

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 5, 2014, Pages 552-559

  Mohan, Divya ^a,i   Gale, Nichola S ^b   McEniery, Carmel M ^c   Bolton, Charlotte E ^d   Cockcroft, John R ^b   MacNee, William ^e   Fuld, Jonathan ^c   Lomas, David A ^f   Calverley, Peter M A ^g   Shale, Dennis J ^b   Miller, Bruce E ^h   Wilkinson, Ian B ^c   Tal Singer, Ruth ^h   Polkey, Michael I ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF LIVERPOOL   (United Kingdom)

^h GLAXOSMITHKLINE   (United States)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Arterial stiffness; Cardiovascular; Extrapulmonary; Fibrinogen; Inflammation; Muscle

Indexed keywords

FIBRINOGEN;

AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR PARAMETERS; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL SYSTEM PARAMETERS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PROSPECTIVE STUDY; PULSE WAVE; QUADRICEPS MAXIMAL VOLUNTARY CONTRACTION FORCE; SIX MINUTE WALK DISTANCE; STAFF TRAINING; ADULT; BREATHING MUSCLE; CARDIOVASCULAR DISEASES; ECHOGRAPHY; EXERCISE TEST; IMMUNOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; MUSCLE STRENGTH; MUSCULAR DISEASES; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUADRICEPS FEMORIS MUSCLE; SMOKING;

ADULT; AGED; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; EXERCISE TEST; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCULAR DISEASES; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULSE WAVE ANALYSIS; QUADRICEPS MUSCLE; RESPIRATORY MUSCLES; SMOKING;

EID: 84907061114     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.898031     Document Type: Article

References (36)

1. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(6 Pt 1):1791-1797.
2. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Euro Respir J 2010; 36(1):81-88.
3. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. ERJ 2012; 40(5):1115-1122.
4. McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, et al. Arterial stiff ness is independently associated wiThemphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176(12):1208-1214.
5. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, et al. Arterial stiff ness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(12):1259-1265.
6. Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(12):1286-93.
7. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classifi cation of lung disease and mortality: fi ndings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100(1):115-122.
8. Sidney S, Sorel M, Quesenberry CP, Jr., DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128(4):2068-2075.
9. Natanek SA, Gosker HR, Slot IG, Marsh GS, Hopkinson NS, Man WD, et al. Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (COPD); implications for stratifi ed medicine Muscle Nerve 2013; 48(4):488-497.
10. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R, Cetti EJ, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Th orax 2007; 62(2):115-120.
11. Gea J, Agusti A, Roca J. Pathophysiology of muscle dysfunction in COPD. J Appl Physiol 2013; 114(9):1222-1234.
12. Troosters T, Gosselink R, Decramer M. Short-and long-term Effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000; 109(3):207-212.
13. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140(2):331-342.
14. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic infl ammation is associated with poor clinical outcomes in COPD: a novel phenotype. PloS One 2012; 7(5):e37483.
15. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fi brinogen as a biomarker of chronic obstructive pulmonary disease. Th orax 2013; 68:670-676.
16. Valvi D, Mannino DM, Mullerova H, Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis 2012; 7:173-182.
17. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Infl ammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186(10):982-988.
18. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12):1128-1138.
19. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). European Respir J 2008; 31(4):869-873.
20. Gale NS, Munnery M, Albarrati A, Munnery I, Shale DJ, Cockcroft JR. Assessment of risk factors in chronic airways disease evaluation (ARCADE). Artery Res 2012; 6(4):158.
21. Casaburi R, Celli B, Crapo J, Criner G, Croxton T, Gaw A, et al. The COPD Biomarker Qualifi cation Consortium (CBQC). J COPD. 2013; 10(3):367-377.
22. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fi brinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367(14):1310-1320.
23. Clauss A. [Rapid physiological coagulation method in determination of fi brinogen]. Acta Haematol 1957; 17(4):237-246.
24. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998; 16(12 Pt 2):2079-2084.
25. Csanyi A, Egervari A. Simple clinical method of average intimamedia thickness measurement in the common carotid artery. VASA Zeitschrift fur Gefasskrankheiten 1996;25(3):242-248.
26. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166(1):111-117.
27. Edwards RH, Young A, Hosking GP, Jones DA. Human skeletal muscle function: description of tests and normal values. Clin Sci Mol Med 1977; 52(3):283-290.
28. Steiner MC, Roubenoff R, Tal-Singer R, Polkey MI. Prospects for the development of Effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review. Th orax 2012; 67(12):1102-1109.
29. Maclay JD, McAllister DA, Mills NL, Paterson FP, Ludlam CA, Drost EM, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(6):513-520.
30. MacNee W. Systemic infl ammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013; 45(3):291-300.
31. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011; 12:146.
32. Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178(12):1211-1218.
33. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012; 106(4):522-530.
34. Moore AJ, Soler RS, Cetti EJ, Amanda Sathyapala S, Hopkinson NS, Roughton M, et al. Sniff nasal inspiratory pressure versus IC/TLC ratio as predictors of mortality in COPD. Respir Med. 2010; 104(9):1319-1325.
35. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with selfreported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49(2):M85-94.
36. Kon SS, Patel MS, Canavan JL, Clark AL, Jones SE, Nolan CM, et al. Reliability and validity of the four metre gait speed in COPD. ERJ 2013; 42(2):333-340.